NASDAQ:CPRX

Catalyst Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CPRX

*Your capital is at risk

$31.49

+0 (+0%)

At Close: Jul 31, 2026

Catalyst Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -100.00. In total, the insiders bought 0 and sold 16.46M CPRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-100.00
● Buy	0 shares
● Sell	16.46M shares
0% Buy Activity Weak Positive Correlation
Sell Signal High Confidence Jul 15, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -100. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (0% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 15, 2026 Sell	Common Stock, par value $0.001 per share D-Return	Sundaram Preethi Chief Strategy Officer	Officer	54 804 Value: $1.73M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Sundaram Preethi Chief Strategy Officer	Officer	68 000 Value: $1.26M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Sundaram Preethi Chief Strategy Officer	Officer	143 193 Value: $2.03M
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Thompson Tamar Director	Director	5 468 Value: $0
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Thompson Tamar Director	Director	18 115 Value: $412.5K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Denkhaus Donald A Director	Director	23 248 Value: $491.0K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Denkhaus Donald A Director	Director	29 524 Value: $417.8K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Denkhaus Donald A Director	Director	15 000 Value: $278.9K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Denkhaus Donald A Director	Director	30 000 Value: $102.6K
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Mcenany Patrick J Chairman Of Board Of Directors	CEO / President	10 540 Value: $0
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Mcenany Patrick J Chairman Of Board Of Directors	CEO / President	43 591 Value: $920.6K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Mcenany Patrick J Chairman Of Board Of Directors	CEO / President	400 000 Value: $1.37M
Jul 15, 2026 Sell	Common Stock, par value $0.001 per share D-Return	Del Carmen Jeffrey Chief Commercial Officer	Officer	14 337 Value: $451.6K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Russo Gregg Chief Hr Officer	Officer	15 000 Value: $232.7K
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Denkhaus Donald A Director	Director	5 468 Value: $0
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Denkhaus Donald A Director	Director	18 115 Value: $412.5K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Del Carmen Jeffrey Chief Commercial Officer	Officer	150 000 Value: $705.0K
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Andrews William T. Chief Medical Officer	Officer	98 652 Value: $2.25M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Andrews William T. Chief Medical Officer	Officer	124 447 Value: $3.10M
Jul 15, 2026 Sell	Common Stock, par value $0.001 per share D-Return	Andrews William T. Chief Medical Officer	Officer	2 309 Value: $72.7K
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Daly Richard J President And CEO	CEO / President	115 283 Value: $0
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Daly Richard J President And CEO	CEO / President	381 948 Value: $8.70M
Jul 15, 2026 Sell	Options to purchase common stock D-Return	Daly Richard J President And CEO	CEO / President	33 500 Value: $155.4K
Jul 15, 2026 Sell	Common Stock, par value $0.001 per share D-Return	Daly Richard J President And CEO	CEO / President	271 266 Value: $8.54M
Jul 15, 2026 Sell	Restricted Stock Units D-Return	Sundaram Preethi Chief Strategy Officer	Officer	32 257 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CATALYST PHARMACEUTICALS

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop...

Read Full Profile Here